Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor

Journal of Cardiology

Volumn 60, Issue 1, 2012, Pages 7-11

  Tanaka, Akihito ^a   Sakakibara, Masaki ^a   Okumura, Satoshi ^a   Okada, Koji ^a   Ishii, Hideki ^b   Murohara, Toyoaki ^b  

^a Handa City Hospital   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Proton pump inhibitor; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; JAPANESE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONFATAL MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RASH; RETROSPECTIVE STUDY; SEX RATIO; SIDE EFFECT; STENT THROMBOSIS; STROKE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84864026977     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.02.003     Document Type: Article

References (26)

1. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., Mansourati J., Mottier D., Abgrall J.F., Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
2. Cuisset T., Frere C., Quilici J., Poyet R., Gaborit B., Bali L., Brissy O., Morange P.E., Alessi M.C., Bonnet J.L. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009, 54:1149-1153.
3. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., Rumsfeld J.S. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
4. O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., Michelson A.D., Hautvast R.W., Ver Lee P.N., Close S.L., Shen L., Mega J.L., Sabatine M.S., Wiviott S.D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989-997.
5. Juurlink D.N., Gomes T., Ko D.T., Szmitko P.E., Austin P.C., Tu J.V., Henry D.A., Kopp A., Mamdani M.M. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-718.
6. Furuta T., Shirai N., Sugimoto M., Nakamura A., Hishida A., Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005, 20:153-167.
7. Farid N.A., Kurihara A., Wrighton S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010, 50:126-142.
8. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102:624-629.
9. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
10. Takayama T., Hiro T., Hirayama A. Stent thrombosis and drug-eluting stents. J Cardiol 2011, 58:92-98.
11. Bovill E.G., Terrin M.L., Stump D.C., Berke A.D., Frederick M., Collen D., Feit F., Gore J.M., Hillis L.D., Lambrew C.T., Leiboff R., Mann K.G., Markis J.E., Pratt C.M., Sharkey S.W., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991, 115:256-265.
12. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Copland I., Fox K.A. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
13. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
14. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
15. Moukarbel G.V., Signorovitch J.E., Pfeffer M.A., McMurray J.J., White H.D., Maggioni A.P., Velazquez E.J., Califf R.M., Scheiman J.M., Solomon S.D. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009, 30:2226-2232.
16. Rao S.V., Eikelboom J.A., Granger C.B., Harrington R.A., Califf R.M., Bassand J.P. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1193-1204.
17. Li X.Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004, 32:821-827.
18. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., Schomig A., Kastrati A., von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 101:714-719.
19. Tsukahara K., Kimura K., Morita S., Ebina T., Kosuge M., Hibi K., Iwahashi N., Endo M., Maejima N., Sugano T., Umemura S. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J Cardiol 2011, 57:275-282.
20. Bhatt D.L., Cryer B.L., Contant C.F., Cohen M., Lanas A., Schnitzer T.J., Shook T.L., Lapuerta P., Goldsmith M.A., Laine L., Scirica B.M., Murphy S.A., Cannon C.P. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
21. Simon T., Steg P.G., Gilard M., Blanchard D., Bonello L., Hanssen M., Lardoux H., Coste P., Lefevre T., Drouet E., Mulak G., Bataille V., Ferrieres J., Verstuyft C., Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011, 123:474-482.
22. Huang C.C., Chen Y.C., Leu H.B., Chen T.J., Lin S.J., Chan W.L., Chen J.W. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010, 105:1705-1709.
23. Bauer T., Bouman H.J., van Werkum J.W., Ford N.F., ten Berg J.M., Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011, 343:d4588.
24. Bouman H.J., Schomig E., van Werkum J.W., Velder J., Hackeng C.M., Hirschhauser C., Waldmann C., Schmalz H.G., ten Berg J.M., Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011, 17:110-116.
25. Stone G.W., Lansky A.J., Pocock S.J., Gersh B.J., Dangas G., Wong S.C., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., Mockel M., Ochala A., Kellock A., Parise H., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009, 360:1946-1959.
26. Seyfarth M., Kastrati A., Mann J.F., Ndrepepa G., Byrne R.A., Schulz S., Mehilli J., Schomig A. Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. Am J Kidney Dis 2009, 54:830-839.